DBD
Diebold Nixdorf, Incorporated Technology - Software - Application Investor Relations →
Diebold Nixdorf, Incorporated (DBD) closed at $71.81 as of 2026-02-02, trading 65.1% above its 200-week moving average of $43.50. The stock moved further from the line this week, up from 59.5% last week. The 14-week RSI sits at 70, indicating neutral momentum.
In 81 weeks of available data, DBD has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.
With a market cap of $2.6 billion, DBD is a mid-cap stock. The company generates a free cash flow yield of 11.1%, which is notably high. Return on equity stands at 4.9%. The stock trades at 2.4x book value.
The company has been aggressively buying back shares, reducing its share count by 52.0% over the past three years.
Over the past 1.7 years, a hypothetical investment of $100 in DBD would have grown to $186, compared to $128 for the S&P 500. That represents an annualized return of 45.3% vs 15.8% for the index — confirming DBD as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Growth of $100: DBD vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
Historical Touches
DBD has not crossed below its 200-week moving average in the available data (81 weeks).
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02